BWBridget Williams

Bridget Williams

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Bridget Williams has a total of 74 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Forecasting LLM‐Enabled Biorisk and the Efficacy of Safeguards

    by Bridget Williams, Luca Righetti, Josh Rosenberg, Rebecca Ceppas de Castro, Otto Kuusela, Rhiannon Britt, Emily Soice, Alvaro Morales, Jon Sanders, Seth Donoughe, et al.

    Capabilities of large language models (LLMs) on several biological benchmarks have prompted not only excitement about their usefulness for research but also concern about biosecurity risks. We recruited 46 subject‐matter experts in biology and biosecurity, and 22 generalist forecasters to estimate the risks of growing LLM capabilities. Most respondents expected some hypothetical LLM capabilities to increase their estimates of risk and dramatically underestimated the rate of LLM progress in those capabilities. When these capabilities arose, the median forecast did update as anticipated. The median expert initially predicted a 0.3% annual risk of a human‐caused epidemic that causes 100,000 deaths. This estimate then rose to 1.5% conditional on several hypothetical LLM capabilities, including matching the performance of a top‐performing team of virologists on a virology troubleshooting test, which the median expert did not expect to occur until 2030. Given this finding, we conducted a baselining study and found that LLMs already crossed this performance threshold in April 2025. A follow‐up survey conducted after these results were available found that forecasters significantly updated their median unconditional risk estimates upward, with the new median expert forecast of annual risk rising to 1.5% (as anticipated by the earlier conditional forecasts). More encouragingly, most experts thought that the adoption of LLM safeguards and mandatory nucleic acid screening would negate the risk associated with some hypothetical LLM capabilities.

  • The impact of point‐of‐care hepatitis C testing in needle and syringe exchange programs on linkage to care and treatment uptake among people who inject drugs: An Australian pilot study

    by Jessica Howell, Michael W. Traeger, Bridget Williams, Chloe Layton, Joseph S. Doyle, Ned Latham, Bridget Draper, Frances Bramwell, Dean Membrey, Maggie McPherson, et al.

    Point‐of‐care (POC) diagnostics overcome barriers to conventional hepatitis C (HCV) testing in people who inject drugs. This study assessed impact on hepatitis C treatment uptake of POC HCV testing in needle and syringe exchange programs (NSPs). Rapid EC was a single‐arm interventional pilot study of HCV POC testing conducted in three inner‐city community clinics with NSPs. Twelve months after the POC testing, a retrospective medical record and Pharmaceutical Benefits Scheme audit was performed to determine the number of HCV RNA‐positive participants who were prescribed HCV treatment. 70 HCV RNA‐positive Rapid EC study participants were included. 44 (63%) were prescribed DAAs; 26 (59%) completed treatment and 15 (34%) had SVR testing, all of whom were cured. Age ≥ 40 years (aOR 3.45, 95% CI 1.10–11.05, p = .03) and secondary school education (aOR 5.8, 95% CI 1.54–21.80, p = .009) had higher likelihood of being prescribed DAAs, whereas homelessness was inversely associated with prescription of DAAs (aOR 0.30, 95% CI 0.09–1.04, p = .057). Median time to receive a DAA script from date of diagnosis was seven days (IQR 0 to 14 days), and time to filling the DAA prescription was 2 days (IQR 0–12 days). In conclusion, provision of POC testing through NSPs was effective for linking new clients to HCV treatment and reduced the time to treatment. Further studies are needed to define the most cost‐effective use of POC testing in models of care for people who inject drugs to increase HCV treatment uptake.


  • Open Access

    Early epidemiological investigations: World Health Organization UNITY protocols provide a standardized and timely international investigation framework during the COVID‐19 pandemic

    by Isabel Bergeri, Hannah C. Lewis, Lorenzo Subissi, Anthony Nardone, Marta Valenciano, Brianna Cheng, Ketevan Glonti, Bridget Williams, Ibukun‐Oluwa Omolade Abejirinde, Alice Simniceanu, et al.

    Background: The declaration of Coronavirus disease 2019 (COVID‐19) as a Public Health Emergency of International Concern (PHEIC) on 30 January 2020 required rapid implementation of early investigations to inform appropriate national and global public health actions.Methods: The suite of existing pandemic preparedness generic epidemiological early investigation protocols was rapidly adapted for COVID‐19, branded the ‘UNITY studies’ and promoted globally for the implementation of standardized and quality studies. Ten protocols were developed investigating household (HH) transmission, the first few cases (FFX), population seroprevalence (SEROPREV), health facilities transmission (n = 2), vaccine effectiveness (n = 2), pregnancy outcomes and transmission, school transmission, and surface contamination. Implementation was supported by WHO and its partners globally, with emphasis to support building surveillance and research capacities in low‐ and middle‐income countries (LMIC).Results: WHO generic protocols were rapidly developed and published on the WHO website, 5/10 protocols within the first 3 months of the response. As of 30 June 2021, 172 investigations were implemented by 97 countries, of which 62 (64%) were LMIC. The majority of countries implemented population seroprevalence (71 countries) and first few cases/household transmission (37 countries) studies.Conclusion: The widespread adoption of UNITY protocols across all WHO regions indicates that they addressed subnational and national needs to support local public health decision‐making to prevent and control the pandemic.


  • Point-of-care hepatitis C testing from needle and syringe programs: An Australian feasibility study

    by Bridget Williams, Jessica Howell, Joseph Doyle, Alexander J. Thompson, Bridget Draper, Chloe Layton, Ned Latham, Frances Bramwell, Dean Membrey, Maggie Mcpherson, et al.


  • Point-of-care Hepatitis C virus testing and linkage to treatment in an Australian inner-city emergency department

    by J. Hutton, J. Doyle, R. Zordan, T. Weiland, A. Cocco, J. Howell, S. Iser, J. Snell, S. Fry, K. New, et al.


  • Community‐based, point‐of‐care hepatitis C testing: perspectives and preferences of people who inject drugs

    by Ned H. Latham, Alisa Pedrana, Joseph S. Doyle, Jessica Howell, Bridget Williams, Peter Higgs, Alexander J. Thompson, Margaret E. Hellard

    Summary: A barrier to hepatitis C treatment for people who inject drugs (PWID) is needing to attend multiple appointments for diagnosis. Point‐of‐care hepatitis C tests provide results within 20 to 105 minutes and can be offered opportunistically in nonclinical settings such as needle syringe programmes. In this nested qualitative study, we explored the acceptability of point‐of‐care testing for PWID. PWID attending participating needle syringe programmes were screened using the OraQuick HCV antibody mouth swab (result in 20 minutes); those with a reactive result then underwent venepuncture for a point‐of‐care RNA test: the Xpert HCV Viral Load (result in 105 minutes). Convenience sampling was used to select participants for a semi‐structured interview. A hybrid thematic analysis was performed, guided by Sekhon's “Theoretical Framework of Acceptability.” Nineteen participants were interviewed. Three core themes emerged: "people and place," "method of specimen collection," and "rapidity of result return." It was highly acceptable to be offered testing at the needle syringeprogrammes by nurses and community health workers, who were described as competent and nonjudgemental. Most participants reported that even if a finger‐stick point‐of‐care RNA test were an option in the future, they would prefer venepuncture, as the sample could be used for pre‐treatment workup and bundled testing. Waiting 20 minutes to receive the antibody test result was acceptable, whereas the 105 minutes required for the RNA result was unacceptable. Offering point‐of‐care hepatitis C testing at needle syringe programmes is acceptable to PWID, however tests that avoid venepuncture are not necessarily the most attractive to PWID.